Fulgent Genetics (NASDAQ:FLGT) Stock Price Up 5.5%

Fulgent Genetics, Inc. (NASDAQ:FLGT)’s stock price traded up 5.5% during mid-day trading on Monday . The stock traded as high as $22.68 and last traded at $22.68. 30,821 shares were traded during trading, a decline of 84% from the average session volume of 198,101 shares. The stock had previously closed at $21.50.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler cut their target price on Fulgent Genetics from $28.00 to $25.00 and set a “neutral” rating on the stock in a report on Wednesday, March 6th.

Fulgent Genetics Stock Performance

The stock has a market capitalization of $642.55 million, a price-to-earnings ratio of -3.86 and a beta of 1.43. The company has a fifty day simple moving average of $21.76 and a 200 day simple moving average of $24.98.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.61. The company had revenue of $70.51 million for the quarter, compared to the consensus estimate of $67.14 million. Fulgent Genetics had a negative return on equity of 2.92% and a negative net margin of 57.72%. As a group, equities analysts predict that Fulgent Genetics, Inc. will post -2.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in FLGT. Asset Management One Co. Ltd. acquired a new position in shares of Fulgent Genetics in the 3rd quarter valued at about $34,000. Cambridge Investment Research Advisors Inc. raised its stake in Fulgent Genetics by 7.0% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 10,572 shares of the company’s stock worth $283,000 after buying an additional 693 shares during the period. Stratos Wealth Partners LTD. raised its stake in Fulgent Genetics by 6.6% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 10,377 shares of the company’s stock worth $277,000 after buying an additional 647 shares during the period. New York State Teachers Retirement System raised its stake in Fulgent Genetics by 6.2% during the 3rd quarter. New York State Teachers Retirement System now owns 23,990 shares of the company’s stock worth $641,000 after buying an additional 1,411 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Fulgent Genetics by 20.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,902 shares of the company’s stock worth $131,000 after buying an additional 828 shares during the period. 48.06% of the stock is owned by institutional investors and hedge funds.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.